Fujifilm Pivots Beyond Film

In the year 2000, Fujifilm and Eastman Kodak stood as twin giants of the photographic film industry. Both companies had built global empires on the same core product: light-sensitive chemical film. Both faced the same existential threat: digital photography was rapidly making that product obsolete. Global demand for photographic film peaked around 2000 and then fell off a cliff, declining roughly 20-30% per year for the next decade. By 2010, the film market had shrunk by over 90%. What happened next is one of the starkest divergences in corporate history. Kodak filed for Chapter 11 bankruptcy in January 2012. Fujifilm, by contrast, was thriving — a $24 billion revenue company with operating margins healthy enough to fund aggressive R&D investment.

The difference was Shigetaka Komori. Appointed CEO of Fujifilm in 2003, Komori had spent his career in the company and understood its capabilities at a molecular level — literally. While the business world saw Fujifilm as a film company, Komori saw it as an advanced chemistry company that happened to sell film. Photographic film manufacturing required mastery of collagen science, antioxidant chemistry, nanotechnology, precision optical coatings, and the manipulation of molecular structures at angstrom-level precision. These were not narrow skills — they were foundational capabilities that could be applied across dozens of industries. Komori's insight was simple but profound: Fujifilm's core competence was not film. It was the science beneath the film.

Komori launched what he called 'VISION 75' — a strategic plan unveiled for the company's 75th anniversary in 2009 — though the diversification began years earlier. He poured $9 billion into R&D and acquisitions between 2000 and 2010, systematically building positions in markets where Fujifilm's chemistry expertise created genuine competitive advantages. In cosmetics, Fujifilm's knowledge of collagen and antioxidants — developed to prevent photos from fading — became the foundation of the Astalift skincare line. In pharmaceuticals, the company's expertise in chemical synthesis and molecular design led to partnerships and acquisitions, including the purchase of Toyama Chemical, whose antiviral drug Avigan would later gain global attention during the COVID-19 pandemic. In flat-panel displays, Fujifilm's optical film coatings became essential components in LCD screens manufactured by Samsung and LG. In medical imaging, the company built on its existing X-ray film business to become a major player in digital diagnostic systems.

The financial transformation was dramatic. In 2000, imaging solutions (primarily film) accounted for roughly 60% of Fujifilm's revenue. By 2019, that figure had fallen below 15%, and film itself was less than 1% of revenue. Yet total revenue had grown. Healthcare and materials solutions now drove the business, with operating profits far exceeding what the old film business had ever generated. Meanwhile, Kodak — which had invented the digital camera in 1975 but refused to cannibalize its film business — had been reduced to a shell of its former self after emerging from bankruptcy in 2013 as a small commercial printing company.

The Fujifilm story is not merely a tale of survival — it is a masterclass in strategic reinvention. Komori understood something that eludes most executives facing disruption: the question is not 'How do we save our product?' but 'What capabilities do we have that the world still needs?' By redefining Fujifilm's identity around its deepest competencies rather than its most visible product, Komori turned an impending death sentence into a second life. The company that once competed with Kodak for shelf space at drugstores now competes with Merck in pharmaceuticals and Shiseido in skincare.